APA (7th ed.) Citation

Dimino, A., Rizzo, M., Fazio, I., Arcara, C., Mortellaro, G., Antonuzzo, L., . . . Incorvaia, L. (2025). 2650P Metastasis-directed therapies (MDT) for oligometastatic (OM) and oligoprogressive (OP) Renal Cell Cancer (RCC) patients with extra-lung metastases: The KAIROS study. Annals of Oncology, 36, S1420. https://doi.org/10.1016/j.annonc.2025.08.3263

Chicago Style (17th ed.) Citation

Dimino, A., et al. "2650P Metastasis-directed Therapies (MDT) for Oligometastatic (OM) and Oligoprogressive (OP) Renal Cell Cancer (RCC) Patients with Extra-lung Metastases: The KAIROS Study." Annals of Oncology 36 (2025): S1420. https://doi.org/10.1016/j.annonc.2025.08.3263.

MLA (9th ed.) Citation

Dimino, A., et al. "2650P Metastasis-directed Therapies (MDT) for Oligometastatic (OM) and Oligoprogressive (OP) Renal Cell Cancer (RCC) Patients with Extra-lung Metastases: The KAIROS Study." Annals of Oncology, vol. 36, 2025, p. S1420, https://doi.org/10.1016/j.annonc.2025.08.3263.